Cargando…

Nonspecific interstitial pneumonia: clinical associations and outcomes

BACKGROUND: Studies have shown that nonspecific interstitial pneumonitis (NSIP), even when initially diagnosed as an idiopathic form of the disease, might be associated with an autoimmune background that later reveals itself as an organ-specific or a systemic autoimmune disease. METHODS: NSIP patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, WenBin, Xiao, Yi, Liu, HongRui, Qin, MingWei, Zheng, WenJie, Shi, JuHong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236489/
https://www.ncbi.nlm.nih.gov/pubmed/25380997
http://dx.doi.org/10.1186/1471-2466-14-175
_version_ 1782345174115942400
author Xu, WenBin
Xiao, Yi
Liu, HongRui
Qin, MingWei
Zheng, WenJie
Shi, JuHong
author_facet Xu, WenBin
Xiao, Yi
Liu, HongRui
Qin, MingWei
Zheng, WenJie
Shi, JuHong
author_sort Xu, WenBin
collection PubMed
description BACKGROUND: Studies have shown that nonspecific interstitial pneumonitis (NSIP), even when initially diagnosed as an idiopathic form of the disease, might be associated with an autoimmune background that later reveals itself as an organ-specific or a systemic autoimmune disease. METHODS: NSIP patients were divided into three groups. The NSIP patients who met the criteria for having a systemic autoimmune disease (SAD) were defined as the systemic autoimmune disease-associated NSIP (SAD-NSIP) group. The NSIP patients who did not meet the criteria for a systemic autoimmune disease were defined as an antibody-positive group (i-NSIP-Ab + group) if their sera were positive for autoantibodies. The NSIP patients with negative serologic tests for auto-antibodies were defined as the antibody-negative group (i-NSIP-Ab- group). The clinical characteristics were analyzed and compared among the three groups. RESULTS: Ninety-seven NSIP patients were included. The mean age of the study population was 48 ± 11 years. The mean follow-up time was 54 ± 34 months. At the time of the surgical lung biopsies, 23/97 (23.7%) of the patients were classified as SAD-NSIP; 30/97 (30.9%) were in the i-NSIP-Ab + group; and 44/97 (45.4%) were in the i-NSIP-Ab- group. At the end of the follow-up period, three cases were diagnosed with polymyositis (one case from the i-NSIP-Ab + group, two cases from the i-NSIP-Ab- group), one with scleroderma (from the i-NSIP-Ab + group, scl-70 positive and skin biopsy) and another one with microscopic polyarteritis (from the i-NSIP-AB-group, p-ANCA and MPO positive, renal biopsy). Three cases in the i-NSIP-Ab- group were later found to be positive for autoantibodies. Due to these changes in classification, at the end of the follow-up period, the SAD-NSIP group consisted of 28/97 patients (28.9%), the i-NSIP-Ab + group of 31/97 (32.0%) and the i-NSIP-Ab- group of 38/97(39.1%). There were no significant differences in clinical manifestations, radiographic findings or pulmonary function tests among the three groups at the time of surgical lung biopsy or after reclassification after the follow-up period. SAD was an independent risk factor for the survival of the patients with NSIP after follow-up. CONCLUSION: Follow-up is recommended because idiopathic NSIP may be the first manifestation of a systemic autoimmune disease.
format Online
Article
Text
id pubmed-4236489
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42364892014-11-19 Nonspecific interstitial pneumonia: clinical associations and outcomes Xu, WenBin Xiao, Yi Liu, HongRui Qin, MingWei Zheng, WenJie Shi, JuHong BMC Pulm Med Research Article BACKGROUND: Studies have shown that nonspecific interstitial pneumonitis (NSIP), even when initially diagnosed as an idiopathic form of the disease, might be associated with an autoimmune background that later reveals itself as an organ-specific or a systemic autoimmune disease. METHODS: NSIP patients were divided into three groups. The NSIP patients who met the criteria for having a systemic autoimmune disease (SAD) were defined as the systemic autoimmune disease-associated NSIP (SAD-NSIP) group. The NSIP patients who did not meet the criteria for a systemic autoimmune disease were defined as an antibody-positive group (i-NSIP-Ab + group) if their sera were positive for autoantibodies. The NSIP patients with negative serologic tests for auto-antibodies were defined as the antibody-negative group (i-NSIP-Ab- group). The clinical characteristics were analyzed and compared among the three groups. RESULTS: Ninety-seven NSIP patients were included. The mean age of the study population was 48 ± 11 years. The mean follow-up time was 54 ± 34 months. At the time of the surgical lung biopsies, 23/97 (23.7%) of the patients were classified as SAD-NSIP; 30/97 (30.9%) were in the i-NSIP-Ab + group; and 44/97 (45.4%) were in the i-NSIP-Ab- group. At the end of the follow-up period, three cases were diagnosed with polymyositis (one case from the i-NSIP-Ab + group, two cases from the i-NSIP-Ab- group), one with scleroderma (from the i-NSIP-Ab + group, scl-70 positive and skin biopsy) and another one with microscopic polyarteritis (from the i-NSIP-AB-group, p-ANCA and MPO positive, renal biopsy). Three cases in the i-NSIP-Ab- group were later found to be positive for autoantibodies. Due to these changes in classification, at the end of the follow-up period, the SAD-NSIP group consisted of 28/97 patients (28.9%), the i-NSIP-Ab + group of 31/97 (32.0%) and the i-NSIP-Ab- group of 38/97(39.1%). There were no significant differences in clinical manifestations, radiographic findings or pulmonary function tests among the three groups at the time of surgical lung biopsy or after reclassification after the follow-up period. SAD was an independent risk factor for the survival of the patients with NSIP after follow-up. CONCLUSION: Follow-up is recommended because idiopathic NSIP may be the first manifestation of a systemic autoimmune disease. BioMed Central 2014-11-07 /pmc/articles/PMC4236489/ /pubmed/25380997 http://dx.doi.org/10.1186/1471-2466-14-175 Text en © Xu et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Xu, WenBin
Xiao, Yi
Liu, HongRui
Qin, MingWei
Zheng, WenJie
Shi, JuHong
Nonspecific interstitial pneumonia: clinical associations and outcomes
title Nonspecific interstitial pneumonia: clinical associations and outcomes
title_full Nonspecific interstitial pneumonia: clinical associations and outcomes
title_fullStr Nonspecific interstitial pneumonia: clinical associations and outcomes
title_full_unstemmed Nonspecific interstitial pneumonia: clinical associations and outcomes
title_short Nonspecific interstitial pneumonia: clinical associations and outcomes
title_sort nonspecific interstitial pneumonia: clinical associations and outcomes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236489/
https://www.ncbi.nlm.nih.gov/pubmed/25380997
http://dx.doi.org/10.1186/1471-2466-14-175
work_keys_str_mv AT xuwenbin nonspecificinterstitialpneumoniaclinicalassociationsandoutcomes
AT xiaoyi nonspecificinterstitialpneumoniaclinicalassociationsandoutcomes
AT liuhongrui nonspecificinterstitialpneumoniaclinicalassociationsandoutcomes
AT qinmingwei nonspecificinterstitialpneumoniaclinicalassociationsandoutcomes
AT zhengwenjie nonspecificinterstitialpneumoniaclinicalassociationsandoutcomes
AT shijuhong nonspecificinterstitialpneumoniaclinicalassociationsandoutcomes